Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) has a higher price-to-earnings ratio of 10.76x compared to its average ratio,, and the 36-month beta value for IRWD is at 0.95.
The public float for IRWD is 150.89M, and currently, shorts hold a 11.35% of that float. The average trading volume for IRWD on May 25, 2023 was 2.45M shares.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
IRWD) stock’s latest price update
The stock price of Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) has plunged by -1.46 when compared to previous closing price of 10.97, but the company has seen a 5.88% gain in its stock price over the last five trading sessions. Barron’s reported on 05/22/23 that Ironwood Pharmaceuticals to Buy VectivBio in $1 Billion Deal. The Sector Is Hot for M&A.
IRWD’s Market Performance
Ironwood Pharmaceuticals Inc. (IRWD) has experienced a 5.88% rise in stock performance for the past week, with a 2.66% rise in the past month, and a -6.33% drop in the past quarter. The volatility ratio for the week is 4.13%, and the volatility levels for the past 30 days are at 2.97% for IRWD. The simple moving average for the last 20 days is 3.43% for IRWD stock, with a simple moving average of -2.72% for the last 200 days.
IRWD Trading at 2.15% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.61% of loss for the given period.
Volatility was left at 2.97%, however, over the last 30 days, the volatility rate increased by 4.13%, as shares surge +3.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.84% upper at present.
During the last 5 trading sessions, IRWD rose by +5.88%, which changed the moving average for the period of 200-days by -7.61% in comparison to the 20-day moving average, which settled at $10.47. In addition, Ironwood Pharmaceuticals Inc. saw -12.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from MCCOURT Thomas A, who sale 36,000 shares at the price of $10.12 back on May 22. After this action, MCCOURT Thomas A now owns 784,916 shares of Ironwood Pharmaceuticals Inc., valued at $364,320 using the latest closing price.
Shetzline Michael, the CMO,SVP,Head-Res&Drug of Ironwood Pharmaceuticals Inc., sale 10,324 shares at $10.12 during a trade that took place back on May 22, which means that Shetzline Michael is holding 321,131 shares at $104,479 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- +60.97 for the present operating margin
- +99.65 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc. stands at +42.64. The total capital return value is set at 23.29, while invested capital returns managed to touch 17.27. Equity return is now at value 29.30, with 17.00 for asset returns.
Based on Ironwood Pharmaceuticals Inc. (IRWD), the company’s capital structure generated 63.75 points at debt to equity in total, while total debt to capital is 38.93. Total debt to assets is 37.79, with long-term debt to equity ratio resting at 63.28. Finally, the long-term debt to capital ratio is 38.65.
When we switch over and look at the enterprise to sales, we see a ratio of 3.51, with the company’s debt to enterprise value settled at 0.20. The receivables turnover for the company is 3.58 and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 30.58.
Conclusion
In conclusion, Ironwood Pharmaceuticals Inc. (IRWD) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
